Literature DB >> 7086128

Presence of auto-anti-idiotypic antibody during the normal human immune response to tetanus toxoid antigen.

R S Geha.   

Abstract

Auto-anti-idiotypic antibodies were searched for in the serum of two individuals who received booster immunization with tetanus toxoid (TT) antigen. IgG from serial bleeds obtained for 4 mo after immunization was studied a) for its capacity to specifically bind 125I IgG F(ab')2 anti-TT prepared from serum obtained 7 and 10 days post-booster immunization, and b) for its capacity (after its absorption with TT) to specifically inhibit the binding of 125I-radiolabeled TT to IgG obtained 7 and 10 days post-immunization and designated "peak IgG." In both individuals studied, auto-anti-Id IgG were detected in both assays as early as 2 wk post-booster immunization and remained detectable throughout the study period. Evidence for modulation of idiotypic expression on IgG F(ab')2 anti-TT after booster immunization with TT was obtained by studying a) the capacity of serial IgG samples to inhibit the binding of 125I-IgG F(ab')2 anti-TT to rabbit anti-Id antibody raised against the IgG F(ab')2 anti-TT, and b) the capacity of the rabbit anti-Id to specifically inhibit the binding of 125I-TT to serial samples of serum IgG. Both assays indicated that some idiotypic determinants present on anti-TT obtained before and shortly after booster immunization were expressed to a much lesser extent 2 wk and beyond after immunization. The decrease in the expression of these determinants coincided with the appearance of auto-anti-Id antibody and remained evident throughout the 4-mo study period. The results obtained indicate that auto-anti-Id antibodies arise in normal human subjects after a secondary challenge with antigen and suggest that these antibodies may play a role in the modulation of idiotypic expression that is observed after booster immunization with antigen.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7086128

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A.

Authors:  M Wettendorff; D Iliopoulos; M Tempero; D Kay; E DeFreitas; H Koprowski; D Herlyn
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

Review 2.  Phenotypic and functional analysis of lymphocytes in myasthenia gravis.

Authors:  A I Levinson; R P Lisak; B Zweiman; M Kornstein
Journal:  Springer Semin Immunopathol       Date:  1985

3.  Demonstration and immunochemical characterization of natural, autologous anti-idiotypic antibodies throughout the course of experimental syphilis.

Authors:  R E Baughn
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

4.  An idiotope-specific autoantibody in SLE.

Authors:  C G Mackworth-Young; R S Schwartz
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

5.  Spontaneous reversal of acquired autoimmune dysfibrinogenemia probably due to an antiidiotypic antibody directed to an interspecies cross-reactive idiotype expressed on antifibrinogen antibodies.

Authors:  A Ruiz-Arguelles
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

6.  Demonstration of anti-idiotypic antibodies directed against IgM rheumatoid factor in the serum of rheumatoid arthritis patients.

Authors:  W K Hancock; E V Barnett
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

7.  Production, isolation, and characterization of rabbit anti-idiotypic antibodies directed against human antithyrotrophin receptor antibodies.

Authors:  J R Baker; Y G Lukes; K D Burman
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

8.  Idiotypic network: possible explanation of seronegativity in a patient with rheumatoid arthritis.

Authors:  J L Pasquali; A Urlacher; D Storck
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

9.  Crossreactivity and inheritance of idiotypes restricted to human anti-tetanus toxoid antibodies.

Authors:  C M Brozek; R S Geha
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

10.  Lower antibody response to tetanus toxoid associated with higher auto-anti-idiotypic antibody in old compared with young humans.

Authors:  E E Arreaza; J J Gibbons; G W Siskind; M E Weksler
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.